FDA approves generic versions of Aciphex
SILVER SPRING, Md. — The Food and Drug Administration has approved six generic versions of a drug used to treat gastroesophageal reflux disease, or GERD, the agency said Friday.
The FDA announced the approval of the first generic versions of Eisai's Aciphex (rabeprazole sodium) delayed-release tablets for patients aged 12 and older. The generic products are made by Dr. Reddy's Labs, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals USA and Torrent Pharmaceuticals.
"Healthcare professionals and consumers can be assured that FDA-approved generic drugs have met the same rigid standards of quality as the brand-name drug," FDA Office of Generic Drugs acting director Kathleen Uhl said. "This medication is widely used by people who have gastroesophageal reflux disease, so it is important to have access to affordable treatment options."